Stock OTLK OUTLOOK THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-03 EDT 		5-day change 1st Jan Change
8.6 USD +1.18% Intraday chart for Outlook Therapeutics, Inc. +2.02% +9.14%
04-15 Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC CI
04-15 Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Outlook Therapeutics Shares Rise After BTIG Upgrade
Outlook Therapeutics Reports Secondary Share Offering
Sector Update: Health Care Stocks Ease Late Afternoon
Sector Update: Health Care Stocks Ease Friday Afternoon
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -
Outlook Therapeutics lève 60 millions de dollars pour l'approbation de son bevacizumab
Outlook Therapeutics Shares Climb Following Upgrade by Chardan
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Outlook Therapeutics Doses First Patient in Eye Disease Study
Outlook Therapeutics, Inc. Doses First Subject in Norse Eight
Sector Update: Health Care Stocks Decline Late Afternoon
Sector Update: Health Care Stocks Softer Tuesday Afternoon
Outlook Therapeutics Says FDA Clarifies Steps for ONS-5010 Study, Enters Securities Purchase Deals
Outlook Therapeutics :bondit après plusieurs bonnes nouvelles pour son produit ONS-5010
Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT
Outlook Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Outlook Therapeutics :réduit ses pertes en 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OTLK Stock
  4. News Outlook Therapeutics, Inc.
  5. Other languages